Statistics from Altmetric.com
As the principal investigators for the Stenting and Aggressive Medical Management for the Prevention of Recurrent Ischemic Stroke (SAMMPRIS) trial,1 we are compelled to address a few inaccuracies regarding this study in the recent editorial by Dr Alexander.2
The first point is the patient population. The SAMMPRIS population was the right patient population to test. We had very good data from the Warfarin versus Aspirin for Symptomatic Intracranial Disease (WASID) trial that patients with recently symptomatic severe stenosis were at the highest risk for recurrent stroke.3 This high-risk population offered the best chance for showing a benefit with …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.